Blue Jet Healthcare Limited has informed the Exchange about Transcript
BLUEJET · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Blue Jet Healthcare reported FY26 revenue of INR947 crores (-8% YoY), with Q4 revenue at INR235 crores. The contrast media segment delivered strong performance with FY26 revenue of INR495 crores (+23% YoY) and Q4 at INR193 crores (+91% YoY), driven by existing customer offtake and new product launches. The PI/API segment faced significant headwinds with FY26 revenue declining 35% to INR298 crores due to customer destocking, though management confirmed destocking is complete and shipments have resumed with confidence to exceed FY25 peak levels. The company is investing heavily in growth infrastructure including a Vizag greenfield project (~INR1,000 crores over 3 years), Mahad backward integration (production start H2 FY27), and Hyderabad R&D center (~INR40 crores). FY27 capex spend is planned at ~INR400 crores. The company remains debt-free with INR400 crores in liquid assets. Management guided for double-digit growth in contrast media for FY27.
The stock is in an investment phase with near-term margin pressure (EBITDA declined to 31% from 37%) due to lower volumes and logistics cost pressures, but improving business visibility and capacity expansion position the company for growth as new products commercialize in FY27.